Health & Fitness:Medicine
This week, we review the major flagship anti-VEGF agents, pegaptinib, ranibizumab, bevacizumab, aflibercept, as well as some of the flagship clinical trials, including VISION, MARINA, ANCHOR, CATT, and VIEW 1 and 2.
Also, we are doing a survey to assess the impact of the podcast. If you'd like to support us, take this 4 minute survey: bit.ly/2VpPRND
More Episodes
Buddy Call-The 20 Point Exam and Red Eyes with Dr. Paul Gaudio!
2019-07-05
9.5k
2019-07-05
9.5k
Lenticular Glaucomas
2019-06-26
8.4k
2019-06-26
8.4k
Macular Holes with Dr Jay Sridhar!
2019-06-19
8.8k
2019-06-19
8.8k
Acute Anterior Uveitis Part 2
2019-06-12
10.7k
2019-06-12
10.7k
Acute Anterior Uveitis Part 1
2019-06-05
11.9k
2019-06-05
11.9k
Atypical Optic Neuritis
2019-05-23
10.0k
2019-05-23
10.0k
Optic Neuritis
2019-05-15
12.3k
2019-05-15
12.3k
Color Vision Deficiency
2019-05-08
9.1k
2019-05-08
9.1k
Ectopia Lentis
2019-04-24
7.6k
2019-04-24
7.6k
EfE Chats with Andrea Tooley, MD!
2019-04-17
6.5k
2019-04-17
6.5k
Ocular Syphilis
2019-04-10
10.2k
2019-04-10
10.2k
Macular Dystrophies
2019-04-03
11.9k
2019-04-03
11.9k
Sickle Cell Retinopathy (+ other manifestations)
2019-03-20
9.7k
2019-03-20
9.7k
Landmark Glaucoma Trials
2019-03-13
13.8k
2019-03-13
13.8k
Nystagmus II + Saccadia
2019-03-06
10.2k
2019-03-06
10.2k
Corneal Dystrophies II + Ectasias
2019-02-27
13.7k
2019-02-27
13.7k
Nystagmus I
2019-02-20
14.2k
2019-02-20
14.2k
Corneal Dystrophies I
2019-02-13
16.8k
2019-02-13
16.8k
Phakomatoses II
2019-02-05
11.5k
2019-02-05
11.5k
Get this podcast on your
phone, FREE
